Reduced Expression of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) in Squamous Cell Carcinoma Complicating Recessive Dystrophic Epidermolysis Bullosa  by Mallipeddi, Rajeev et al.
Reduced Expression of Insulin-Like Growth Factor-Binding
Protein-3 (IGFBP-3) in Squamous Cell Carcinoma Complicating
Recessive Dystrophic Epidermolysis Bullosa
Rajeev Mallipeddi,1 Vesarat Wessagowit,1 Andrew P. South, Alistair M. Robson,w Guy E. Orchard,w
Robin A. J. Eady, and John A. McGrath
Genetic Skin Disease Group and wDepartment of Dermatopathology, St John’s Institute of Dermatology, The Guy’s, Kings College, St Thomas’ Hospitals’ Medical
School, St Thomas’ Hospital, London, UK
Squamous cell carcinoma (SCC) is a common complication in individuals with recessive dystrophic epidermolysis
bullosa (RDEB). For the severe Hallopeau–Siemens subtype, the mortality rate from SCC is over 55% by the age of
40 y. Currently, little is known about the molecular pathology or cell biology of SCC in RDEB. In this study, we
compared gene expression in RDEB SCC (n¼ 3) and non-EB SCC (n¼ 3) with corresponding RDEB and non-EB
peri-tumoral skin, with microarray analysis using DermArray membranes as well as semi-quantitative and real-time
RT-PCR. Both tumor sets showed downregulation of epidermal differentiation markers (e.g., proﬁlaggrin, keratins 1
and 10) as well as certain pro-apoptotic genes (e.g., death-associated kinase-3 or ZIP kinase). Likewise, in both
groups there was upregulation of matrix metalloproteinase 1 and laminin 5 in the tumors. But we found that the
expression of insulin-like growth factor-binding protein-3 (IGFBP-3) was lower (mean of 5.8-fold) in RDEB SCC
compared with non-EB SCC. These data were veriﬁed by immunohistochemistry. IGFBP-3 has an important role in
cancer cell apoptosis mediated via the nuclear retinoid X receptor a (RXRa). Reduced expression of IGFBP-3 in
RDEB SCC may provide a partial explanation for the aggressive behavior and poor prognosis of these tumors in
this genodermatosis.
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Squamous cell carcinoma (SCC) is a significant cause of
morbidity and mortality in the severe autosomal recessive
(Hallopeau–Siemens) subtype of dystrophic epidermolysis
bullosa (RDEB) (OMIM #226600). In these individuals, the
cumulative risk is 76.5% by 60 y and over 55% die due to
SCC by 40 y (Fine et al, 1999). The tumors occur mostly
overlying bony prominences on limbs, where blistering and
scarring tend to be most severe (Mallipeddi, 2002). Most
RDEB-associated SCC are well-differentiated but can
metastasize relatively rapidly and the histological grade is
not always a reliable predictor of behavior (McGrath et al,
1992). The reason for the aggressive nature and poor
prognosis of these SCC is unclear. In vitro studies have
shown reduced numbers of poorly functional natural killer
cells (Tyring et al, 1989) as well as abnormal peripheral
mononuclear cell cytokine production (Chopra et al, 1990),
changes that could result in reduced immune surveillance.
Furthermore, it has been proposed that repetitive tissue
ulceration leads to loss of cellular differentiation thereby
promoting tumor development (Goldberg et al, 1988).
Keratinocytes expressing a growth-activated phenotype
have been found in RDEB, in both recently healed wounds
and wounds that had been healed for over 2 y, suggesting
that RDEB keratinocytes may have a pre-malignant poten-
tial (Smoller et al, 1990).
Currently, however, there are little data regarding muta-
tion analysis of cancer-related genes in RDEB SCC or loss
of heterozygosity studies, methylation status analyses, or
gene expression profiles. In this study, we have compared
the gene expression profiles of RDEB SCC and non-EB
SCC using microarray analysis. Differences in expression
were then assessed further by semi-quantitative and real-
time RT-PCR, as well as skin immunohistochemistry using
an anti-IGFBP-3 antibody; the latter technique also being
applied to other archival EB and non-EB SCC material. The
data disclosed differences in expression of insulin-like
growth factor-binding protein-3 (IGFBP-3) a mediator of
apoptosis (Lee and Cohen, 2002), with relatively lower
expression in RDEB SCC than non-EB SCC.
Results
DermArray ﬁlters show consistent gene expression data
on repeat hybridizations Image analysis was performed
on the DermArray membrane following five cycles of
hybridization, stripping and re-probing. Pearson’s correla-1These authors contributed equally to this work.
Abbreviations: IGFBP-3, insulin-like growth factor-binding protein-
3; MMP1, matrix metalloproteinase 1; RDEB, recessive dystrophic
epidermolysis bullosa; RXR, retinoid X receptor; SCC, squamous
cell carcinoma
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tion, used to measure the reproducibility of the data sets,
was calculated to compare the first and subsequent
probings. Correlation reduced significantly after fourth use
(see Table S1), indicating signal degradation. These data
indicate that DermArray filters provide a consistent and
reproducible gene expression profile on repeat hybridiza-
tions up to four times.
cDNA microarray analysis in SCC and peri-tumoral skin
reveals differential gene expression changes In compar-
ing SCC with peri-tumoral skin, 50 genes in the RDEB group
(10 upregulated and 40 downregulated) and 58 genes in the
non-RDEB group (11 upregulated and 47 downregulated)
showed differential expression in all three data sets. Details
of the differently expressed genes are shown in Tables S2
and S3. As discussed later, however, the DermArray results
did not always correlate perfectly with semi-quantitative RT-
PCR findings.
Genes altered in both RDEB and non-EB group
comparisons (SCC vs peri-tumoral skin) included those
related to epidermal differentiation (profilaggrin and keratin
10) and the pro-apoptotic death-associated protein kinase
3 (ZIP kinase), all of which were downregulated. Keratin 1
was also downregulated in RDEB SCC and two of three
non-EB SCC data sets. Matrix metalloproteinase 1 (MMP1,
interstitial collagenase) and laminin 5 (g2 chain) were
upregulated in the non-EB SCC and were also upregulated
in two of three RDEB data sets.
Comparison of RDEB and non-EB SCC microarray data
reveals relatively lower expression of IGFBP-3 in RDEB
SCC When the three data sets comparing RDEB SCC and
non-EB SCC were analyzed, eight genes consistently
exhibited differential gene expression (five upregulated
and three downregulated). These are detailed in Table S4.
Of these, IGFBP-3 showed the most marked difference.
Specifically, there was an average 5.8-fold reduction in
RDEB SCC expression. In addition, the microarray data
showed relatively downregulated expression of MMP1
(average of 5.2-fold) in RDEB SCC.
Direct comparison of RDEB and non-EB peri-tumoral
skin revealed that P-cadherin was differentially expressed,
being lower in the non-EB group (average of 3.0-fold);
however, no other major differences in relative peri-tumoral
gene expression were observed.
Semi-quantitative RT-PCR and real-time RT-PCR con-
ﬁrm differences in IGFBP-3 expression To verify the
DermArray hybridization data, RT-PCR was used to amplify
some of the changes detected. Examples included IGFBP-3
(Fig 1A), MMP1 (Fig 1B), laminin 5 (Fig 1C), profilaggrin (Fig
1D), keratin 1 (Fig 1E), and keratin 10 (Fig 1F). For most
genes, the semi-quantitative RT-PCR data supported the
hybridization data after normalizing and comparing band
intensities. But there were some discrepancies between
the DermArray and the RT-PCR data. For example, using
DermArray, three genes appeared on the list of differentially
expressed genes in one sample group only (keratin 1
downregulated in RDEB SCC; MMP1 and laminin 5 both
upregulated in non-EB SCC). They were altered similarly,
however, in two of three specimens in the other sample
group and when semi-quantitative RT-PCR was performed
it was found that they were actually altered in all three
specimens from both groups, i.e., that there was a
consistent change in both RDEB and non-EB SCC. Thus,
some of the differences that appear in comparing the data
in Tables S2 and S3 reflect a lack of consistency in all the
DermArray data. This was also evident for expression of
the type VII collagen gene, COL7A1, although all spots on
the filter for this gene in all hybridizations were very faint
approaching the lower limit of detection (including in non-
EB control skin), findings that may lead to artifactual
observations in subsequent image data analysis. Further-
more, COL7A1 mutation analysis revealed that one RDEB
patient was a compound heterozygote for a nonsense
mutation/glycine substitution, an additional factor that may
also reduce the differences in COL7A1 gene expression
levels between RDEB and control samples. Nonetheless,
for the other two RDEB cases (one with nonsense mutations
on both alleles and the other in whom mutation analysis has
not yet been performed but whose skin biopsy anti-type VII
collagen labeling was undetectable), gene expression
would be expected to be lower in the peri-tumoral skin.
By DermArray, however, consistently reduced COL7A1
expression in all RNA samples from the EB subjects was
not seen. By contrast, for more robust analysis, semi-
Figure1
Semi-quantitative RT-PCR data confirm relatively reduced expres-
sion of IGFBP-3 but not MMP1 in RDEB SCC compared with non-
EB SCC. Resolved RT-PCR products derived from the following
samples: 1¼RDEB peri-tumoral skin, 2¼RDEB SCC, 3¼non-EB
peri-tumoral skin, and 4¼non-EB SCC. Ratios of the gene-specific
product relative to the internal standard ribosomal 18S are displayed
between each resolved PCR product (to one decimal point). Where no
product is seen the ratio is substituted by N/A (not assessable). (A)
IGFBP-3 expression is relatively reduced in RDEB SCC compared with
non-EB SCC (data set 1, ratio 5.7). By contrast, (B) MMP1 (data set 3,
0.9) and (C) laminin-5 (data set 2, ratio 3.0) are upregulated in SCC of
both groups. (D) Profilaggrin (data set 2, ratio N/A), (E) keratin 1 (data
set 3, ratio N/A), and (F) keratin 10 (data set 3, ratio N/A) are
downregulated in the SCC of both groups; (G) an example of the
reduced expression of COL7A1 expression in RDEB peri-tumoral skin
compared with non-EB peri-tumoral skin (data set 2) is also shown.
Ratios of gene expression comparing non-EB and RDEB groups are
shown above in the brackets and calculated as (non-EB SCC/non-EB
peri-tumoral skin) over (RDEB SCC/RDEB peri-tumoral skin) to one
decimal point. IGFBP-3, insulin-like growth factor-binding protein-3;
MMP1, matrix metalloproteinase 1; RDEB, recessive dystrophic
epidermolysis bullosa; SCC, squamous cell carcinoma.
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quantitative RT-PCR was also performed with peri-tumoral
skin RNA samples to compare COL7A1 expression be-
tween RDEB and non-EB and this approach confirmed
lower COL7A1 gene expression in all the RDEB group (Fig
1G).
Conversely, some of the consistent changes in gene
expression demonstrated by DermArray were not substan-
tiated by RT-PCR. For example, when the RDEB SCC and
non-EB SCC were compared directly with DermArray,
MMP1 appeared to have a lower expression in all of the
specimens of RDEB SCC (Table S4), however, this was not
confirmed by RT-PCR (Fig 1B).
Another interesting result from DermArray and RT-PCR
expression data also emerged. The DermArray data showed
no significant changes in IGFBP-3 expression between SCC
normalized against peri-tumoral skin in RDEB (ratio SCC/
peri-tumoral skin, 1.3, 1.8, 0.6, respectively) but revealed
upregulation in two of three non-EB SCC (ratio SCC/peri-
tumoral skin, 4.5, 7.4, 1.1, respectively). Semi-quantitative
RT-PCR results in the former (RDEB SCC/peri-tumoral skin
1.1-, 4.9-, and 0.8–fold, respectively) and the latter (non-EB
SCC/peri-tumoral skin, 6.4-, 6.8-, and 1.7-fold, respectively)
showed a similar trend. When comparing the normalized
ratios of RDEB SCC over non-EB SCC, IGFBP-3 expression
was consistently reduced by an average of a 3.14-fold by
DermArray (1.3/4.5, 1.8/7.4, and 0.6/1.1), and 3.11-fold
reduction by RT-PCR (1.1/6.4, 4.9/6.8, and 0.8/1.7) (see
Fig 1A, for first data set results, patients 1 and 2).
To investigate these findings further, RNA from samples
in data sets 2 and 3 were analyzed using real-time RT-PCR.
The results for IGFBP-3 confirmed reduced normalized
expression in RDEB SCC compared with non-EB SCC with
more marked differences than semi-quantitative RT-PCR
(ratio of (non-EB SCC/peri-tumoral skin) over (RDEB
SCC/peri-tumoral skin) was 5.7 and 5.9 in the respective
data sets and an average of a 5.8-fold reduction in RDEB
SCC).
No differences in RXR expression were evident using
real-time RT-PCR analysis IGFBP-3 mediates apoptosis
by binding to RXRa and therefore to further examine other
genes relevant to IGFBP-3 function, RXRa expression was
determined. Only the b and g isoforms of RXR were present
on the DermArray membrane and these showed no
significant differences in gene expression between SCC
and peri-tumoral skin in either group. Therefore, we used
real-time RT-PCR to assess RXRa, but did not find any
differential gene expression between SCC and peri-tumoral
skin in either group (ratio of (non-EB SCC/peri-tumoral skin)
over (RDEB SCC/peri-tumoral skin) was 1.8 and 1.1 in the
data sets, respectively).
Immunohistochemistry reveals relatively less IGFBP-3
expression in RDEB SCC compared with non-EB SCC In
both RDEB and non-EB peri-tumoral skin, IGFBP-3 labeling
was present in keratinocyte cytoplasm in a pan-epidermal
distribution (Fig 2A and C). In seven of 11 RDEB SCC no
increase in expression was detected (Fig 2B). In 20 of 21
non-EB SCC, however, there was enhanced expression in
SCC compared with peri-tumoral epidermis (Fig 2D),
whereas this was the case in only four of 11 RDEB SCC.
In five non-EB SCC, there was clearly accentuated staining
at the periphery of tumor islands and in three there was
more intense staining focally within the tumor. Of the
archival age- and site- and differentiation-matched non-
EB controls, eight of 10 SCC showed a diffuse increase in
cytoplasmic IGFBP-3 immunostaining in the tumor and an
additional case showed a focal increase in labeling in some
SCC islands. In both the EB and non-EB SCC material,
neither the intensity nor distribution of immunopositivity
varied with degree of differentiation or other clinico-
pathological factors.
Discussion
This is the first report of gene expression analysis in SCC
complicating RDEB. Although there are no specific diag-
nostic markers for human SCC (Alam and Ratner, 2001),
we have shown a pattern of gene expression changes com-
mon to both RDEB and non-EB SCC that are consistent
with the development of squamous neoplasia, including
Figure2
Immunohistochemical labeling with anti-IGFBP-3 antibody shows
reduced expression in RDEB SCC compared with non-EB SCC. (A)
RDEB peri-tumoral skin showing cytoplasmic pan-epidermal staining.
(B) RDEB SCC with diffuse staining throughout the tumor in a similar
pattern to (A). (C) Non-EB peri-tumoral skin showing similar epidermal
staining to (A). (D) Non-EB SCC revealing more marked cytoplasmic
expression, compared with peri-tumoral skin, within the tumor. (E)
Negative control (omitting primary antibody) shows no labeling. The
RDEB and non-EB skin sections illustrated are from patients 3 and 4,
respectively. Scale bar: 100 mm. IGFBP-3, insulin-like growth factor-
binding protein-3; RDEB, recessive dystrophic epidermolysis bullosa;
SCC, squamous cell carcinoma.
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downregulation of epidermal differentiation markers (profi-
laggrin, keratin 1, and keratin 10), genes related to apoptosis
(death-associated protein kinase-3 or ZIP kinase), and
upregulation of MMP1 (interstitial collagenase) and laminin
5 (g2 chain) when compared with peri-tumoral skin. These
changes support other data demonstrating disruption of
normal squamous differentiation in neoplasia with loss of
filaggrin expression (Klein-Szanto et al, 1984) as well as
keratins 1 and 10 (Kartasova et al, 1992). Death-associated
protein kinase-3 (ZIP kinase) shares 80% homology with
death-associated protein kinase (Kawai et al, 1998), which
has reduced expression in various cancer cell lines (Cohen
and Kimchi, 2001). As for the upregulated genes, degrada-
tion of the extracellular matrix by metalloproteinases is
relevant in growth, invasion, and metastasis (Basset et al,
1997; Johansson and Ka¨ha¨ri, 2000), and MMP1, a protei-
nase capable of degrading fibrillar collagens, has been
shown to have an enhanced expression in malignant
keratinocytes and fibroblasts in vivo compared with benign
cells (Airola and Fusenig, 2001). Laminin 5, a key structural
component of the epidermal basement membrane, is also
important in carcinoma migration and invasion (Lohi, 2001).
Notably, overexpression of the g2 chain of laminin 5 has
been demonstrated in a variety of carcinomas including SCC
(Pyke et al, 1994; Lohi, 2001; Patel et al, 2002).
Comparison of RDEB and non-EB peri-tumoral skin gene
expression revealed only two differences, with P-cadherin
being more expressed by DermArray and downregulation of
COL7A1 by RT-PCR. The latter change is consistent with
inherent loss-of-function mutations in type VII collagen
being the cause of RDEB (Jarvikallio et al, 1997). Upregula-
tion of P-cadherin in the epidermis has been noted
previously in the lesional skin of both acquired and inherited
blistering skin diseases, and may reflect a high local
proliferative activity (Hakuno et al, 2001). Overall, the few
differences observed in gene expression between RDEB
and non-EB peri-tumoral skin is not surprising, given that a
comparison of the gene expression profiles of cultured
keratinocytes from another form of inherited EB (non-Herlitz
junctional EB) patients and normal controls using cDNA
microarray filters similar to ours, also revealed no major
differences between EB cells and controls (Huber et al,
2002).
An intriguing observation in our study, however, was the
altered relative expression of IGFBP-3 in SCC. We found a
reduced expression of IGFBP-3 in EB SCC compared with
non-EB SCC relative to corresponding peri-tumoral skin
using microarray analysis, semi-quantitative RT-PCR, real-
time PCR and immunohistochemistry. The IGFBP are a
family of seven structurally homologous proteins that bind
IGF-I and -II and modulate their growth-promoting and
metabolic effects (Oh, 1997). Most IGF-I and -II in serum are
found in ternary complexes formed by an IGF, IGFBP-3/
IGFBP-5, and a glycoprotein acid labile subunit (Baxter,
1994) and IGFBP-3 is the major circulating carrier protein for
IGF (Baxter, 2001). Most tissue IGF are bound to IGFBP as
binary complexes (Lee and Cohen, 2002). IGFBP-3 has
been shown to be an important mediator of cancer cell
apoptosis by modulating IGF but also by IGF-independent
mechanisms (Lee and Cohen, 2002). The pro-apoptotic
effects of IGFBP-3 have been illustrated in several types
including breast (Schedlich and Graham, 2002), lung (Lee
et al, 2002), and prostate cancers (O’Brien et al, 2001).
Reduced IGFBP-3 gene expression has been associated
with prostate cancer progression, with greater loss of
expression in more advanced disease (Hampel et al,
1998; Grimberg and Cohen, 1999). Reduced IGFBP-3 gene
expression (by cDNA microarray) has also been observed in
hepatocellular carcinoma compared with normal liver tissue
(Chung et al, 2002) and reduced IGFBP-3 protein expres-
sion (assessed by immunohistochemistry) has been de-
tected in stage 1 non-small cell lung cancer, correlating with
a worse prognosis (Chang et al, 2002). The level of IGFBP-3
protein expression in colonic epithelial cells correlates with
p53 status and wild-type p53 cells secrete higher levels of
IGFBP-3 than mutant p53 cell lines (Collard et al, 2003).
Furthermore, higher levels of serum IGF-I and lower serum
IGFBP-3 have been associated with an increased risk of
prostate (Chan et al, 1998), early breast (Hankinson et al,
1998), lung (Yu et al, 1999), colorectal (Giovannucci, 2001),
and bladder cancers (Zhao et al, 2003).
It is now clear that IGFBP-3 also has a significant IGF-
independent pro-apoptotic effect and that this is mediated
via the nuclear RXRa (Lee and Cohen, 2002). Indeed, a
study comparing IGFBP-3 treatment of a F9 embryonic
carcinoma cell line with a sister RXRa knockout line showed
dramatically reduced cell viability in the former but no
obvious effects in the latter (Lee and Cohen, 2002). IGFBP-3
mRNA and protein expression are also induced by other
apoptotic-inducing and anti-proliferative factors including
tumor necrosis factor-a (TNF-a) (Rozen et al, 1998; Rajah
et al, 2002), transforming growth factor-b (TGF-b) (Oh et al,
1995; Rajah et al, 1997), p53 (Buckbinder et al, 1995),
1,25 dihydroxyvitamin D3 (Huynh et al, 1998; Boyle et al,
2001), and retinoids (Gucev et al, 1996; Han et al, 1997).
It has been proposed that IGFBP-3 induces apoptosis by
promoting serine phosphorylation of bcl-2, which increases
the inactive bcl-2 form and results in a bcl-2:bax ratio in
favor of apoptosis induction (Rajah et al, 2002). IGFBP-3
activity can also be modulated by proteolytic enzymes
including serine proteases such as prostate specific
antigen, g-nerve growth factor (Rajah et al, 1996) and
plasmin (Booth et al, 1999).
Our study represents a report of abnormal IFGBP-3
expression in cutaneous SCC. Notably, we have shown
consistent downregulation of this gene in RDEB SCC
compared with non-EB SCC relative to corresponding
peri-tumoral skin. Gene expression of the IGFBP-3 receptor,
RXR-a, was not altered in any of the data sets. The relative
differences in IGFBP-3 expression were supported by
immunohistochemical analysis of 11 RDEB and 21 non-EB
SCC. Labeling showed that 20 of 21 non-EB SCC had more
intense staining compared with adjacent non-dysplastic
skin, whereas this was detected in only four of 11 RDEB
SCC. In all tumors with increased IGFBP-3 immunolabeling,
the pattern was diffuse, uniform, and cytoplasmic. But in
five of 11 non-EB SCC there was additional, more intense
focal staining in the peripheral tumor layer and, in three
cases, in the central part, of SCC islands. These findings
may reflect zones in which there is the highest cell pro-
liferation, leading to greater induction of pro-apoptotic IGFBP-
3, as a counter measure.
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Biologically, it is unclear why there should be relatively
less upregulation or even downregulation of IGFBP-3 in
RDEB SCC. Certainly there were no significant changes in
the microarray gene expression of any agents known to
induce IGFBP-3 expression including TNF-a, TGF-b, p53, or
1,25 dihydroxyvitamin D3 receptor. None of our patients
was receiving oral retinoids or vitamin D supplements and
there was no data available on the relative activities of
the serine proteases capable of inactivating IGFBP-3. In
addition, human papilloma virus (HPV) association in any
of the patients has not been investigated. This may be of
relevance since HPV-16 E7 protein, which is capable of
overriding cellular senescence, is known to bind to IGFBP-
3, trigger its proteolytic cleavage and thereby have an effect
capable of inhibiting IGFBP-3-mediated apoptosis (Mann-
hardt et al, 2000). To the best of our knowledge, there are no
comprehensive data examining HPV in RDEB SCC.
This is a study to identify reduced IGFBP-3 expression in
RDEB SCC compared with non-EB SCC. The relatively
lower expression of this pro-apoptotic protein in RDEB SCC
may, at least in part, help explain the aggressive nature of
these tumors in RDEB, although further work is needed to
determine the etiology of this reduced expression. It will
also be interesting to examine whether IGFBP-3 has a role
in the pathogenesis and behavior of SCC that develop in
other chronic cicatrizing dermatoses such as burn scars
(Copcu et al, 2003).
The reduced IGFBP-3 expression in RDEB SCC may also
have therapeutic relevance. Specifically, it has been shown
that IGFBP-3 and the specific rexinoid (RXR ligand),
LG1069 (bexarotene or Targretin; Ligand Pharmaceuticals
Inc., San Diego, California), have additive effects in killing
prostate cancer cells (Liu et al, 2000). Our findings provide a
rationale for trials in RDEB using newer rexinoids such as
bexarotene (Targretin), which has been approved for the
treatment of cutaneous T cell lymphoma (Duvic et al,
2001a, b) and which has been tried with partial success in
treating metastatic breast cancer (Esteva et al, 2003) and
non-small cell lung cancer (Khuri et al, 2001). It is plausible
that bexarotene may be useful in preventing or treating
RDEB-associated SCC by compensating for the reduced
IGFBP-3 expression, notwithstanding the practical obser-
vation that oral retinoids typically result in increased skin
fragility in RDEB individuals. Nevertheless, it is clear that the
IGFBP-3/RXRa ligand-receptor axis and pathway deserves
further attention in striving to develop better management
strategies and cancer chemoprophylaxis for sufferers of this
devastating inherited skin disorder.
Materials and Methods
Human tissues and RNA extraction This study was approved by
the St Thomas’ Hospital Research Ethics Committee and all
samples were used with informed consent. Six millimeter punch
biopsies were taken from previously histologically confirmed
cutaneous SCC from three severe recessive RDEB patients and
three non-EB patients after surgical excision. Reproducibility
assessment of reprobing filters was done by using keratinocyte
culture total RNA from normal control skin. The subjects/tumors
were as follows. Patient 1 (RDEB); 35 y, well-differentiated SCC on
dorsum of right hand. Patient 2 (non-EB); 84 y, moderately dif-
ferentiated SCC on left ear. Patient 3 (RDEB); 33 y, moderately
differentiated SCC on left shin. Patient 4 (non-EB); 84 y, moderate-
ly differentiated SCC on left temple. Patient 5 (RDEB); 52 y,
moderately differentiated SCC on dorsum of right hand. Patient 6
(non-EB); 79 y, moderately differentiated SCC on left ear. Peri-
tumoral skin without clinical evidence of SCC was also obtained
from each patient. None of the tumors showed histological
evidence of perineural or vascular invasion. Samples were
immediately placed into RNAlater stabilization reagent (Qiagen
Ltd, Crawley, West Sussex, UK) at room temperature and stored at
201C. Total RNA was extracted from each tissue sample and
DNase treated using the RNeasy Minikit according to the
manufacturer’s protocol (Qiagen Ltd). RNA quality assessment
was done by electrophoresis on a 1% native agarose gel, be-
fore use.
cDNA microarray membrane Human DermArray Genefilters DNA
microarray membranes were purchased from Invitrogen (Paisley,
Scotland, UK). These are nylon membranes printed with 5171
sequence-verified human cDNAs as individual immobilized spots,
and include 4405 unique cDNAs. Of these, 3706 are empirically
chosen genes spotted once, and 517 are specifically selected
genes commonly used in dermatology research: the latter are
spotted in replicates, i.e., 132 are spotted twice, 352 thrice, 26
four times, 1 five times, and 6 six times. Each spot contains
approximately 0.5 ng of clone cDNA.
RNA labeling For each labeling, 2.5 mg of total RNA made up to 8
mL with RNase free H2O (Invitrogen) was incubated with 2 mL of
oligo dT (0.2 mg per mL; Invitrogen) at 701C for 10 min. The mix
was then immediately placed on ice for 2 min and spun down.
Next, a stock solution of 30 mL of 5  RT buffer (Invitrogen), 7.5 mL
ultrapure dNTP mix containing dATP, dGTP, dTTP at 20 mM
(Invitrogen), 5 mL RNase inhibitor (30 U per mL, Invitrogen), 6 mL
AMV reverse transcriptase (25 U per mL; Invitrogen), 1.5 mL RNase,
DNA free H2O (Invitrogen) and 50 mL [a-
33P]dCTP (10 mCi per mL;
Amersham Biosciences, Little Chalfont, Bucks, UK) was made
for four labeling reactions. Twenty microliters of this stock was
aliquoted into each RNA tube and incubated at 421C for 2 h. The
labeled first strand cDNA probes were purified with S.N.A.P.
columns (Invitrogen) and the radioactivity measured with a
scintillation counter to determine the appropriate amount of cDNA
probe required to make a hybridization solution of 2.5  106
counts per mL. The appropriate volume of cDNA probe was then
made up to a total volume of 200 mL with water and denatured at
1001C in a heat block for 3 min.
Hybridization and exposure Ten milliliters MicroHyb hybridiza-
tion solution (Invitrogen), 10 mg denatured Cot-1 DNA (Invitrogen)
and 10 mg poly-dA were added to a HybAid glass roller bottle
containing a DermArray membrane, which was pre-treated for first-
time use by gently agitating in boiling 0.5% sodium dodecyl sulfate
(SDS) for 10 min before pre-hybridization. The membranes were
pre-hybridized at 421C for at least 2 h and then different probes
were added to corresponding hybridization bottles and hybridiza-
tion was performed at 421C for 15 h. The membranes were
individually washed twice at 501C with 2  SSC, 1% SDS for
20 min and once at 551C with 0.5  SSC, 1% SDS for 15 min. Moist
filters were placed on Whatman paper (Whatman International
Ltd., Maidstone, Kent, UK) moistened with TEx1, wrapped
individually and sealed in plastic bags, carefully oriented and
exposed to low energy phosphor imaging screens (Amersham
Biosciences) for 72 h. Filters were stripped by being briskly
agitated in boiling 0.5% SDS for 1 h, sealed as previously
described and re-exposed to a phosphor screen to check for
stripped efficacy before re-use. Three sets of parallel hybridiza-
tions with RNA extracted from one RDEB SCC, corresponding
RDEB peri-tumoral skin, one histological grade-matched non-EB
SCC and corresponding non-EB peri-tumoral skin were performed
on the same day. Thus, there were 12 hybridizations in total.
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Image and data acquisition Exposed screens were scanned
(Storm 840 Phosphoimager, Molecular Dynamics Inc., Sunnyvale,
California) and saved as 16-bit gray scale TIFF files. The TIFF
images were imported into Pathways 4 software (Invitrogen) and
analyzed. The original intensity of each spot representing a unique
gene expression level was acquired. Data normalization was done
by dividing all values with the overall mean of that particular array.
Reproducibility of hybridization data Although the study design
was based on comparison of three EB and three non-EB SCC and
per-tumoral skin samples, with only changes in all three microarray
data sets being considered significant (and then for further
assessment by RT-PCR and immunohistochemistry), it was
important to establish that the same RNA source gave reprodu-
cible expression data on repeat hybridizations using the DermArray
filters. Control keratinocyte culture-derived total RNA was labeled
and hybridized (as described above). The images were acquired
and analyzed (as above). The filter was then stripped as previously
described. The process of reprobing was repeated four times. To
assess similarities (or differences) in the gene expression profiles in
the subsequent hybridizations, statistical analysis using Pearson’s
correlation was performed.
Experimental data analysis There were three biological replicate
data sets of RDEB SCC, RDEB peri-tumoral skin, non-EB SCC,
and non-EB peri-tumoral skin in total. Only data derived from RNA
samples labeled and hybridized on the same day were compared.
Initially, the gene expression profile of RDEB SCC was compared
with RDEB peri-tumoral skin, whereas non-EB SCC was compared
with non-EB peri-tumoral skin, the rationale being to determine,
which genes were differentially expressed in SCC. Subsequently,
RDEB SCC and non-EB SCC gene expression was compared
directly. At least a 2-fold change in gene expression between
samples was considered significant and genes that exhibited this
in all three data sets were filtered.
Semi-quantitative RT-PCR using QuantumRNA 18S internal
standard Standard reverse-transcription reactions were per-
formed at 421C using 2.5 mg of the total RNA extracted from the
samples used for microarray analysis, dNTPs, and M-MuLV reverse
transcriptase and random hexamers as primers (Promega, South-
ampton, Hants, UK). Quantification of individual gene products
using QuantumRNA 18S internal standard primers (Ambion (Eur)
Ltd, Huntingdon, Cambridgeshire, UK) as control was performed
according to the manufacturer’s instructions. Briefly, the linear
range of amplification of a particular primer pair was determined,
then co-amplified with the appropriate mixture of alternate 18S
primers:competimers to yield PCR products with similar band
intensities. Selected genes of interest (see Results) were amplified
and all semi-quantitative RT-PCR experiments were performed
in triplicate with three different biological samples. Primers and
PCR conditions used are shown in Table S5. PCR products were
separated by electrophoresis on 2.5% agarose gels and photo-
graphed using a Polaroid gel camera (Polaroid Corporation,
Waltham, Massachusetts). Prints were then scanned and the band
intensities quantified using Scion Image software for Windows,
version Beta 4.0.2. (http://www.scioncorp.com). The level of gene
expression in each sample was normalized against the amount of
18S product within the same lane (expressed as a ratio).
Real-time RT-PCR The ABI prism 7000 Sequence Detection
System (Applied Biosystems, Foster City, California) was used to
assess transcript levels of IGFBP-3 and retinoid X receptor a
(RXRa) (see Results) in the same samples used for microarray
analysis. IGFBP-3 primers were designed using the Applied
Biosystems Assay-by-Design system (forward, 50-GCAGACCTC-
GGTGTGGAC-30; reverse, 50-TGAGACCCCTCTGTTTTCAAGGA-
30). RXRa (Assay ID, Hs00172565_m1). Housekeeping gene primer
mix Cyclophilin A (Assay ID, Hs99999904_m1) was ordered as a
commercially available Assay-on-Demand product. All primer-
probe mixes were pre-optimized by Applied Biosystems. Real-
time PCR was performed in 25 mL reactions consisting of 900 nM
of each primer mix, 12.5 mL Taqman Universal Master Mix (no
UNG), and cDNA template. Cycling conditions were 2 min at 501C,
10 min at 951C, followed by 40 cycles of 15 s at 951C and 1 min at
601C. Amplicons were quantified on a cycle-by-cycle basis by the
emission intensities. All experiments were performed in duplicate
with two different biological samples. Transcript levels in the
various samples were calculated after normalization to the internal
reference standard, cyclophilin A.
Immunohistochemistry Anti-IGFBP-3 antibody was purchased
from Sigma-Aldrich (Gillingham, Dorset, UK). Eleven RDEB SCC
and 21 non-EB SCC archival tissue samples were examined,
including sections from the same tumors used in this study for
microarray and RNA expression analyses. Because of the
discrepancies in the age and site of tumors in the EB/non-EB
subjects, the additional SCC samples were selected to balance
these inherent differences. The ages of the extra non-EB SCC
subjects was 32–50 y (mean 42.6 y). By comparison, the ages of the
EB SCC cases for this part of the study were 22–53 y (mean 35.5 y).
The non-EB individuals comprised six renal transplant patients,
two psoriasis-PUVA cases, one cutaneous T-cell lymphoma-PUVA
case, and one case of Netherton’s syndrome. The tumors in these
cases were sited on the limbs rather than face/scalp and the degree
of tumor differentiation was also matched to the EB SCC samples.
For the RDEB SCC, three were well differentiated, seven were
moderately differentiated, and one was poorly differentiated. For
the non-EB SCC, the corresponding numbers were five, 15, and
one, respectively. Paraffin-embedded sections (4 mm thick) were
dewaxed in xylene, rehydrated in alcohol and blocked for
endogenous peroxidase by incubation with 3% v/v H2O2 in
methanol. Following antigen retrieval, achieved by microwaving in
a citrate buffer (pH 6.0) for 15 min, slides were incubated with
primary antibody at a 1:40 dilution (antibody diluent; Dako,
Cambridge, UK) for 30 min. The chemMate/HRP detection system
(Dako) was used. This involved 30 min incubation with a universal
biotinylated secondary layer, followed by a tertiary layer with
streptavidin/biotin HRP complex for 30 min. Diamino benzidine was
used as the chromogen and hematoxylin as the counterstain.
Primary antibody was replaced by Tris-buffered saline for negative
controls. All slides were assessed by the same dermatopathologist.
Funding support from the Dystrophic Epidermolysis Bullosa Research
Association (DEBRA UK) and the Royal Thai Government is gratefully
acknowledged. We also thank Balbir Bhogal for his technical
assistance.
Supplementary Material
The following material is available from http://www.blackwellpublishing.
com/products/journals/suppmat/JID/JID22525/JID22525sm.htm
Table S1. Correlation matrix of reusability testing.
Table S2. Differentially expressed genes in RDEB SCC compared
to peri-tumoral skin.
Table S3. Differentially expressed genes in non-EB SCC compared
to peri-tumoral skin.
Table S4. Differentially expressed genes in RDEB SCC compared
to non-EB SCC.
Table S5. Primers and PCR conditions used for semi-quantitative
RT-PCR.
DOI: 10.1111/j.0022-202X.2004.22525.x
Manuscript received August 16, 2003; revised December 6, 2003;
accepted for publication January 6, 2004
Address correspondence to: Dr John McGrath, Genetic Skin Disease
Group, St John’s Institute of Dermatology, St Thomas’ Hospital,
Lambeth Palace Road, London, SE1 7EH, UK. Email: john.mcgrath@
kcl.ac.uk
REDUCED IGFBP-3 IN SCC COMPLICATING RDEB 1307122:5 MAY 2004
References
Airola K, Fusenig NE: Differential stromal regulation of MMP-1 expression in
benign and malignant keratinocytes. J Invest Dermatol 116:85–92, 2001
Alam M, Ratner D: Cutaneous squamous-cell carcinoma. N Engl J Med 344:
975–983, 2001
Basset P, Okada A, Chenard M-P, et al: Matrix metalloproteinases as stromal
effectors of human carcinoma progression: Therapeutic implications.
Matrix Biol 15:535–541, 1997
Baxter RC: Insulin-like growth factor binding proteins in the human circulation: A
review. Horm Res 42:140–144, 1994
Baxter RC: Signalling pathways involved in antiproliferative effects of IGFBP-3: A
review. Mol Pathol 54:145–148, 2001
Booth BA, Boes M, Dake BL, Bar RS: Isolation and characterization of plasmin-
generated bioactive fragments of IGFBP-3. Am J Physiol 276:E450–E454,
1999
Boyle BJ, Zhao XY, Cohen P, Feldman D: Insulin-like growth factor binding
protein-3 mediates 1 alpha, 25-dihydroxyvitamin d(3) growth inhibition
in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:
1319–1324, 2001
Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR,
Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53.
Nature 377:646–649, 1995
Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I
and prostate cancer risk: A prospective study. Science 279:563–566,
1998
Chang YS, Kong G, Sun S, et al: Clinical significance of insulin-like growth factor-
binding protein-3 expression in stage I non-small cell lung cancer. Clin
Cancer Res 8:3796–3802, 2002
Chopra V, Tyring SK, Johnson L, Fine JD: Patients with severe forms of inherited
epidermolysis bullosa exhibit decreased lymphokine and monokine
production. J Clin Immunol 10:321–329, 1990
Chung EJ, Sung YK, Farooq M, et al: Gene expression profile analysis in human
hepatocellular carcinoma by cDNA microarray. Mol Cells 14:382–387,
2002
Cohen O, Kimchi A: DAP-kinase: From functional gene cloning to establishment
of its role in apoptosis and cancer. Cell Death Differ 8:6–15, 2001
Collard TJ, Guy M, Butt AJ, Perks CM, Holly JM, Paraskeva C, Williams AC:
Transcriptional upregulation of the insulin-like growth factor binding
protein IGFBP-3 by sodium butyrate increases IGF-independent apop-
tosis in human colonic adenoma-derived epithelial cells. Carcinogenesis
24:393–401, 2003
Copcu E, Aktas A, Sisman N, Oztan Y: Thirty-one cases of Marjolin’s ulcer. Clin
Exp Dermatol 28:138–141, 2003
Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for treatment
of refractory advanced-stage cutaneous T-cell lymphoma: Multinational
phase II–III trial results. J Clin Oncol 19:2456–2471, 2001
Duvic M, Martin AG, Kim Y, et al: Phase 2 and 3 clinical trial of oral bexarotene
(Targretin capsules) for the treatment of refractory or persistent early-
stage cutaneous T-cell lymphoma. Arch Dermatol 137:581–593, 2001
Esteva FJ, Glaspy J, Baidas S, et al: Multicenter phase II study of oral bexarotene
for patients with metastatic breast cancer. J Clin Oncol 21:999–1006,
2003
Fine JD, Johnson LB, Suchindran C, et al: Cancer and inherited epidermolysis
bullosa: Lifetable analyses of the national epidermolysis bullosa registry
study population. In: Fine JD, Bauer EA, McGuire J, Moshell A (eds).
Epidermolysis Bullosa. Clinical, Epidemiologic, and Laboratory Advances
and the Findings of the National Epidermolysis Bullosa Registry.
Baltimore: The Johns Hopkins University Press, 1999; p 175–192
Giovannucci E: Insulin, insulin-like growth factors and colon cancer: A review of
the evidence. J Nutr 131:3109S–3120S, 2001
Goldberg GI, Eisen AZ, Bauer EA: Tissue stress and promotion. Possible
relevance to epidermolysis bullosa. Arch Dermatol 124:737–741, 1988
Grimberg A, Cohen P: Growth hormone and prostate cancer: Guilty by asso-
ciation? J Endocrinol Invest 22:64–73, 1999
Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG: Insulin-like growth factor binding
protein 3 mediates retinoic acid- and transforming growth factor beta2-
induced growth inhibition in human breast cancer cells. Cancer Res
56:1545–1550, 1996
Hakuno M, Akiyama M, Shimizu H, Wheelock MJ, Nishikawa T: Upregulation of P-
cadherin expression in the lesional skin of pemphigus, Hailey–Hailey
disease and Darier’s disease. J Cutan Pathol 28:277–281, 2001
Hampel OZ, Kattan MW, Yang G, et al: Quantitative immunohistochemical
analysis of insulin-like growth factor binding protein-3 in human prostatic
adenocarcinoma: A prognostic study. J Urol 159:2220–2225, 1998
Han GR, Dohi DF, Lee HY, et al: All-trans-retinoic acid increases transforming
growth factor-beta2 and insulin-like growth factor binding protein-3
expression through a retinoic acid receptor-alpha-dependent signaling
pathway. J Biol Chem 272:13711–13716, 1997
Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-
like growth factor-I and risk of breast cancer. Lancet 1351:1393–1396,
1998
Huber A, Yee C, Darling TN, Yancey KB: Comprehensive analysis of gene
expression profiles in keratinocytes from patients with generalized
atrophic benign epidermolysis bullosa. Exp Dermatol 11:75–81, 2002
Huynh H, Pollak M, Zhang JC: Regulation of insulin-like growth factor (IGF) II and
IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells
by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol
13:137–143, 1998
Jarvikallio A, Pulkkinen L, Uitto J: Molecular basis of dystrophic epidermolysis
bullosa: Mutations in the type VII collagen gene (COL7A1). Hum Mutat
10:338–347, 1997
Johansson N, Ka¨ha¨ri VM: Matrix metalloproteinases in squamous cell carcino-
mas. Histol Histopathol 15:225–237, 2000
Kartasova T, Roop DR, Yuspa SH: Relationship between the expression of
differentiation-specific keratins 1 and 10 and cell proliferation in epi-
dermal tumors. Mol Carcinogen 6:18–25, 1992
Kawai T, Matsumoto M, Takeda K, Sanjo H, Akira S: ZIP kinase, a novel serine/
threonine kinase which mediates apoptosis. Mol Cell Biol 18:1642–1651,
1998
Khuri FR, Rigas JR, Figlin RA, et al: Multi-institutional phase I/II trial of oral
bexarotene in combination with cisplatin and vinorelbine in previously
untreated patients with advanced non-small-cell lung cancer. J Clin Oncol
19:2626–2637, 2001
Klein-Szanto AJ, Barr RJ, Reiners JJ Jr, Mamrack MD: Filaggrin distribution in
keratoacanthomas and squamous cell carcinoma. Arch Pathol Lab Med
108:888–890, 1984
Lee HY, Chun KH, Liu B, et al: Insulin-like growth factor binding protein-3 inhibits
the growth of non-small cell lung cancer. Cancer Res 62:3530–3537,
2002
Lee KW, Cohen P: Nuclear effects: Unexpected intracellular actions of insulin-like
growth factor binding protein-3. J Endocrinol 175:33–40, 2002
Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P: Direct
functional interactions between insulin-like growth factor-binding protein-
3 and retinoid  receptor-alpha regulate transcriptional signaling and
apoptosis. J Biol Chem 275:33607–33613, 2000
Lohi J: Laminin-5 in the progression of carcinomas. Int J Cancer 15:763–767,
2001
Mallipeddi R: Epidermolysis bullosa and cancer. Clin Exp Dermatol 27:616–623,
2002
Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Durr P,
Zwerschke W: Human papillomavirus type 16 E7 oncoprotein binds and
inactivates growth-inhibitory insulin-like growth factor binding protein 3.
Mol Cell Biol 20:6483–6495, 2000
McGrath JA, Schofield OMV, Mayou BJ, McKee PH, Eady RA: Epidermolysis
bullosa complicated by squamous cell carcinoma: Report of 10 cases.
J Cutan Pathol 19:116–123, 1992
O’Brien MF, Watson RW, Fitzpatrick JM: Insulin-like growth factor I and prostate
cancer. Urology 58:1–7, 2001
Oh Y: IGFBPs and neoplastic models. New concepts for roles of IGFBPs in
regulation of cancer cell growth. Endocrine 7:111–113, 1997
Oh Y, Muller HL, Ng L, Rosenfeld RG: Transforming growth factor-beta-induced
cell growth inhibition in human breast cancer cells is mediated through
insulin-like growth factor-binding protein-3 action. J Biol Chem 270:
13589–13592, 1995
Patel V, Aldridge K, Ensley JF, et al: Laminin-gamma2 overexpression in
head-and-neck squamous cell carcinoma. Int J Cancer 99:583–588,
2002
Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, Tryggvason K: The
gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading
malignant cells in human cancers. Am J Pathol 145:782–791, 1994
Rajah R, Bhala A, Nunn SE, Peehl DM, Cohen P: 7S nerve growth factor is
an insulin-like growth factor-binding protein protease. Endocrinology
137:2676–2682, 1996
Rajah R, Lee KW, Cohen P: Insulin-like growth factor binding protein-3 mediates
necrosis factor-alpha-induced apoptosis: Role of Bcl-2 phosphorylation.
Cell Growth Differ 13:163–171, 2002
Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3
induces apoptosis and mediates the effects of transforming growth
factor-beta1 on programmed cell death through a p53- and IGF-inde-
pendent mechanism. J Biol Chem 272:12181–12188, 1997
Rozen F, Zhang J, Pollak M: Antiproliferative action of necrosis factor-alpha
on MCF-7 breast cancer cells is associated with increased insulin-like
1308 MALLIPEDDI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
growth factor binding protein-3 accumulation. Int J Oncol 13:865–869,
1998
Schedlich LJ, Graham LD: Role of insulin-like growth factor binding pro-
tein-3 in breast cancer cell growth. Microsc Res Technol 59:12–22,
2002
Smoller BA, McNutt NS, Carter DM, Gottlieb AB, Hsu A, Krueger J: Recessive
dystrophic epidermolysis bullosa skin displays a chronic growth-acti-
vated immunophenotype. Implications for carcinogenesis. Arch Dermatol
126:78–83, 1990
Tyring SK, Chopra V, Johnson L, Fine JD: Natural killer cell activity is reduced
in patients with severe forms of inherited epidermolysis bullosa. Arch
Dermatol 125:797–800, 1989
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like
growth factor-I and lung cancer risk: A case–control analysis. J Natl
Cancer Inst 91:151–156, 1999
Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X: Plasma levels of
insulin-like growth factor-1 and binding protein-3, and their association
with bladder cancer risk. J Urol 169:714–717, 2003
REDUCED IGFBP-3 IN SCC COMPLICATING RDEB 1309122:5 MAY 2004
